Lancet Gastroenterology & Hepatology

Article	Citations
Liver injury in COVID-19: management and challenges	1313
Prolonged presence of SARS-CoV-2 viral RNA in faecal samples	1244
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017	790
Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis	733
Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible?	580
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis	548
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis	455
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation stu	396
SARS-CoV-2 in wastewater: potential health risk, but also data source	373
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis	345
COVID-19 and the liver: little cause for concern	316
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-labe	294
Effect of a deep-learning computer-aided detection system on adenoma detection during colonoscopy (CADe-DB trial): a double-blind randomised study	265
Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study	246
Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis	244
Early detection of pancreatic cancer	240
Implications of COVID-19 for patients with pre-existing digestive diseases	235
Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study	234
The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease St	220
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis	219
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study	209
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, pha	197
COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy	195
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach	194
Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study	185

Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	182
The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection	173
Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	160
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study	143
Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder	142
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study	140
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study	138
Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial	133
Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden	132
Probiotics and COVID-19: one size does not fit all	131
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis	127
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis	126
Global multi-stakeholder endorsement of the MAFLD definition	123
Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study	119
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement	116
Redefining fatty liver disease: an international patient perspective	115
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial	114
Enteric involvement in hospitalised patients with COVID-19 outside Wuhan	113
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial	112
Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis	110
Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis	106
Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, par	105
Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study	104
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial	102
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement	102
Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel	101
Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study	100
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial	100
Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis	98
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study	98
Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa	97
The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease	96
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study	95
Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial	95
Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial	94
Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study	93
Ultra-processed foods and human health: from epidemiological evidence to mechanistic insights	90
Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver dise	88
Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis	88
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis	88
Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study	86
Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens	85
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomi	85
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority st	84
Determining risk factors for mortality in liver transplant patients with COVID-19	82
Preoperative oral antibiotics and surgical-site infections in colon surgery (ORALEV): a multicentre, single-blind, pragmatic, randomised controlled trial	81
Global prevalence of hepatitis C virus in children in 2018: a modelling study	78
Gastrointestinal sequelae 90 days after discharge for COVID-19	77
Current and emerging therapies for advanced biliary tract cancers	77
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial	77

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial	76
Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group	75
Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study	75
Obesity: another ongoing pandemic	74
Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study	74
Risk of colorectal cancer incidence and mortality after polypectomy: a Swedish record-linkage study	72
The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial	72
Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China	71
Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement	71
Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines	70
Implications of gastrointestinal manifestations of COVID-19	70
Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period	69
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial	68
Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium	67
COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry	67
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis	66
The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017	65
Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis	64
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm,	63
Current and potential treatments for primary biliary cholangitis	63
Breaking the therapeutic ceiling in drug development in ulcerative colitis	63
Computer-aided detection versus advanced imaging for detection of colorectal neoplasia: a systematic review and network meta-analysis	63
Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial	62
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial	61
Drinking alone: COVID-19, lockdown, and alcohol-related harm	60
Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad	60
The knowns and unknowns of treatment for alcoholic hepatitis	59
Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey	59
Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis	57
Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study	56
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial	55
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives	55
The effect of sleep on gastrointestinal functioning in common digestive diseases	55
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial	54
Green endoscopy: a call for sustainability in the midst of COVID-19	54
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review	54
Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases	54
Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial	52
Global reporting of progress towards elimination of hepatitis B and hepatitis C	52
The overlap between irritable bowel syndrome and organic gastrointestinal diseases	50
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised tr	50
The impact of COVID-19 on hepatitis elimination	49
Screening FMT donors during the COVID-19 pandemic: a protocol for stool SARS-CoV-2 viral quantification	49
Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial	49
The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study	48
Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial	48
Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis	48
Liver transplantation in patients with alcohol-related liver disease: current status and future directions	48
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study	47
SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question	46
Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study	46
Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis	46
Inflammation and malnutrition in inflammatory bowel disease	46
Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by	45
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review	45
Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass	44
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study	42
The intestinal barrier in disorders of the central nervous system	42
The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial	42
Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis	42
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial	42
Effect of a deep learning-based system on the miss rate of gastric neoplasms during upper gastrointestinal endoscopy: a single-centre, tandem, randomised controlled trial	41
Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a populat	41
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials	41
Efficacy of surgical or endoscopic treatment of idiopathic achalasia: a systematic review and network meta-analysis	40
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial	40
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide,	40
Drug-induced liver injury in older people	40
Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study	40
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial	40
Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled,	39
Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health	39
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study	39
Stigma and irritable bowel syndrome: a taboo subject?	39
Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium	39
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial	39
Prevention and treatment of nutritional complications after bariatric surgery	38
Predicting endoscopic activity recovery in England after COVID-19: a national analysis	38
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	38
Aggressive fluid hydration plus non-steroidal anti-inflammatory drugs versus non-steroidal anti-inflammatory drugs alone for post-endoscopic retrograde cholangiopancreatography pancreatitis (FLUYT): a	37

Diversity in clinical trials: an opportunity and imperative for community engagement	37
The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis	37
Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial	37
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled	37
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial	36
The role of mucins in gastrointestinal barrier function during health and disease	34
Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials	34
Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (O	34
Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework	33
Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial	33
Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroentero	33
Sleep and liver disease: a bidirectional relationship	33
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial	32
Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak	32
Redefining non-alcoholic fatty liver disease: what's in a name?	32
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study	32
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study	32
Roles of the gut virome and mycobiome in faecal microbiota transplantation	32
Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study	32
Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective	31
One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial	31
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial	31
Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia	31
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)	30
Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus	30
Small molecule oral targeted therapies in ulcerative colitis	30
Probiotics and COVID-19	30
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial	30
Colorectal cancer screening in the USA in the wake of COVID-19	30
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomis	30
Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic	30
Diabetes following acute pancreatitis	29
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis	29
New advances in the treatment of paediatric functional abdominal pain disorders	29
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis	28
Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward	28
Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-	28
Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial	28
Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group	28
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study	28
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease	27
Once-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial	27
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study	26
Global hepatitis C elimination: an investment framework	26
The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease	26
A model of the economic benefits of global hepatitis C elimination: an investment case	26
Barriers to the management of alcohol use disorder and alcohol-associated liver disease: strategies to implement integrated care models	26
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study	25
The phases of hepatitis C elimination: achieving WHO elimination targets	25
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative	25
Increasing burden of colorectal cancer in China	25
Resuming liver transplantation amid the COVID-19 pandemic	25
Fully automated magnetically controlled capsule endoscopy for examination of the stomach and small bowel: a prospective, feasibility, two-centre study	25
Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study	24
Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study	24
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial	24
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	24
Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study	24
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas	24
Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial	23
Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa	23
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission	23
Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?	23
Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma	23
The relationship between gastrointestinal cancers and the microbiota	23
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicent	23
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial	22
Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial	22
Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial	22
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study	22
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study	21
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study	21
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial	21
Global disparities in faecal microbiota transplantation research	21
Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial	20
Faecal immunochemical testing in the COVID-19 era: balancing risk and costs	20
Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study	20
Pancreatic cancer: a state of emergency?	20
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial	20
Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial	20
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial	20
Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis	20
Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analy	20
USPSTF recommends expansion of colorectal cancer screening	19
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial	19
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase	19
Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial	19
Update on the mesentery: structure, function, and role in disease	19
Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis	18
Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system	18
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of	18
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	18
Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis	18
Anal cancer and precancerous lesions: a call for improvement	18
Effect of the COVID-19 pandemic on viral hepatitis services in sub-Saharan Africa	18